Brazil's "no PIP failure reports" contrasts with growing scale of concern
This article was originally published in Clinica
Despite the dearth of official information on the Poly Implant Prothèse (PIP) breast implant crisis, there is growing evidence that the failure rates reported by some national regulators do not reflect the true scale of the problem.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.